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ABSTRACT AND KEYWORDS 
Background: We conducted a phase I dose-escalation study of RO5323441, a novel anti-
placental growth factor (PlGF) monoclonal antibody, to establish the recommended dose for use 
with bevacizumab and to investigate the pharmacokinetics, pharmacodynamics, 
safety/tolerability, and preliminary clinical efficacy of the combination. 
Methods: Twenty-two patients with histologically confirmed glioblastoma in first relapse were 
treated with a two-weekly cycle of RO5323441 (625 mg, 1250 mg or 2500 mg) plus 
bevacizumab 10 mg/kg. A standard “3+3” dose escalation trial design was used. 
Results: RO5323441 combined with bevacizumab was generally well tolerated and the 
maximum tolerated dose was not reached. Two patients experienced dose limiting toxicities 
(Grade 3 meningitis associated with spinal fluid leak [1250 mg] and Grade 3 cerebral infarction 
[2500 mg]). Common adverse events included hypertension (14 patients/64%), headache 
(12/55%), dysphonia (11/50%) and fatigue (6/27%). 
The pharmacokinetics of RO5323441 were linear over the dose range investigated and 
bevacizumab exposure was unaffected by RO5323441 co-administration. Modulation of 
plasmatic angiogenic proteins, with increases in VEGFA and decreases in FLT4, was observed. 
Dynamic contrast-enhanced/diffusion-weighted MRI revealed large decreases in vascular 
parameters that were maintained through the dosing period. Combination therapy achieved an 
overall response rate of 22.7%, including one complete response, and a median progression-free 
and overall survival of 3.5 and 8.5 months, respectively. 
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Conclusion: The toxicity profile of RO5323441 plus bevacizumab was acceptable and 
manageable. The observed clinical activity of the combination does not appear to improve on 
that obtained with single-agent bevacizumab in patients with recurrent glioblastoma. 
Word count: 244 
 
Keywords: RO5323441, placental growth factor, bevacizumab, glioblastoma, dose-escalation 
study 
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INTRODUCTION 
Tumor angiogenesis is a fundamental step in carcinogenesis,1 and the vascular endothelial 
growth factor (VEGF) family of glycoproteins (VEGFA to D [FIGF] and the placental growth 
factor [PGF/PlGF]) are central to this process.2,3 PlGF is a pleiotropic, pro-angiogenic growth 
factor that can stimulate tumor angiogenesis directly by affecting endothelial cells, pericytes and 
smooth muscle cells, and indirectly by enhancing VEGF-driven angiogenesis and by attracting 
pro-angiogenic myeloid cells.4 PlGF expression is increased in some tumor types and can 
correlate with tumor stage and poor outcomes, including disease progression and reduced 
survival.5–7 
Glioblastoma is the most aggressive malignant primary brain tumor in adults and a primary 
target for anti-angiogenic therapy due to the high degree of vascularization.8,9 Several VEGF 
pathway-targeting drugs have emerged, including cediranib, aflibercept, and the anti-VEGF 
monoclonal antibody bevacizumab, which is both active and well tolerated in patients with 
glioblastoma. Based on the durable objective response rates (ORRs) demonstrated in two phase 
II trials,10,11 in 2009 the FDA granted the accelerated approval of single-agent bevacizumab for 
the treatment of patients with progressive glioblastoma following prior therapy.12 However, 
eventual disease progression is inevitable because of the emergence of resistance to VEGF and 
VEGR receptor (VEGFR/KDR)-directed therapy.13 
Simultaneous blockade of multiple angiogenic pathways might improve efficacy and reduce 
therapeutic resistance. Evidence indicates that PlGF is up-regulated in response to VEGF(R) 
inhibition, supporting the development of combined therapy that targets both VEGFA and 
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PlGF.14,15 RO5323441 (RG7334/TB-403) is a humanized recombinant immunoglobulin G1 
(IgG1) anti-PlGF monoclonal antibody. Unlike VEGF, PlGF selectively binds VEGFR1 (FLT1) 
and its co-receptors neuropilin-1 (NRP1) and -2 (NRP2).16 Preclinical studies have shown that 
RO5323441 inhibits the growth of VEGF blockade-resistant tumors without affecting healthy 
vessels.16 RO5323441 is also capable of enhancing the efficacy of chemotherapy and VEGFR 
inhibitors in vivo, and inhibiting angiogenesis and tumor cell motility.16,17 Single-dose 
RO5323441 displayed a favorable safety profile and dose-linear pharmacokinetics (PK) in a 
first-in-human dose-escalation trial.18 A subsequent phase I study of 23 patients with advanced 
solid tumors showed that RO5323441 was well tolerated up to a dose of 30 mg/kg every 3 
weeks; no dose-limiting toxicities (DLTs) were reported and hence the maximum tolerated dose 
(MTD) was not reached.19 PK analysis confirmed the dose-proportional exposure of RO5323441 
with a terminal half-life of 9–14 days. 
Here we report the results of a phase I study that investigated RO5323441 combined with 
bevacizumab in patients with recurrent glioblastoma. The primary objective was to establish the 
recommended dose of RO5323441 for use with bevacizumab. Secondary objectives included 
evaluation of the PK, pharmacodynamics (PD), safety/tolerability and preliminary efficacy of the 
combination treatment.
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METHODS 
Study design 
Study NCT01308684 was a phase Ib, open-label, dose-escalation multicenter study of 
RO5323441 combined with bevacizumab in patients with recurrent glioblastoma. The study was 
conducted at four centers in Switzerland, France, Denmark, and the United Kingdom. Local 
ethics committee approval was obtained and all patients were able to provide their own written 
informed consent. The study was conducted in accordance with Good Clinical Practice and the 
Declaration of Helsinki. 
From Day 1 onwards, three fixed doses of RO5323441 (625, 1250 and 2500 mg) were 
administered once every 2 weeks (q2w) with 10 mg/kg bevacizumab. A standard “3+3” dose-
escalation study design was used to determine the MTD based on the occurrence of DLTs. At the 
MTD or top dose level (set at 2500 mg), six additional patients were enrolled into an expansion 
cohort to further evaluate safety/tolerability, PK and PD. This cohort received pretreatment with 
single-agent bevacizumab (10 mg/kg) on Day -14 and Day 1, single-agent RO5323441 (2500 
mg) on Day -2 with combination therapy given q2w from Day 15 onwards. This dosing schedule 
was selected to allow us to first measure the PD effects of bevacizumab monotherapy, after 
which any additional PD effect due to combination dosing with RO5323441 could be 
determined. Patients continued treatment until disease progression, unacceptable toxicity, 
investigator decision, or patient refusal. 
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Patients 
Eligible patients were ≥18 years of age with histologically confirmed glioblastoma in first 
relapse and radiographic evidence of disease progression. Patients had received standard 
frontline radiotherapy and temozolomide (TMZ), had a Karnofsky performance status ≥70% and 
adequate hematologic (absolute neutrophil count ≥1,500/L; platelets ≥100,000/L), hepatic and 
renal function. Following radio-chemotherapy, a minimum treatment interval of 12 weeks was 
required to reduce the likelihood of pseudo-progression. Patients receiving corticosteroids had to 
be on a stable or decreasing dose for ≥5 days before a baseline MRI scan was conducted. 
Exclusion criteria included previous treatment with PlGF/VEGF(R) targeting agents, cilengitide, 
enzastaurin, or intracerebral agents, MRI evidence of recent brain hemorrhage, uncontrolled 
arterial hypertension or prior history of hypertensive crisis/encephalopathy, prior bleeding 
diathesis or coagulopathy, major surgery and hemoptysis within 1 month, or a history of 
significant cerebro-/cardio-vascular disease, abdominal fistula, gastrointestinal perforation or 
intracranial abscess within 6 months. 
Study drug administration 
RO5323441 and bevacizumab were administered as continuous intravenous (IV) infusions. 
RO5323441 was administered immediately prior to bevacizumab. 
Safety assessments 
Patients were seen before each study drug administration and weekly during the first 4 weeks. 
Safety assessments included physical (performance status, vital signs) and laboratory 
examinations, as well as twice-daily measurement of blood pressure for the first 4 weeks. 
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Baseline and end of study assessments included electrocardiograms (ECGs) and lower extremity 
ultrasounds. Adverse events (AEs) were defined according to the NCI Common Terminology 
Criteria for AEs (CTCAE), version 4.0.20 
Definition of dose-limiting toxicity and maximum tolerated dose 
A DLT was defined as a study drug-related CTCAE that occurred during the first 28 days of 
treatment with RO5323441 plus bevacizumab. These included: Grade (G) 4 neutropenia or 
thrombocytopenia; G3 thrombocytopenia with bleeding; febrile neutropenia and/or documented 
infection requiring IV antibiotics; any non-hematologic G4 event or G3 event that caused a 
dosing delay of >7 days (except for G3 nausea/vomiting, diarrhea, and skin AEs without 
adequate supportive care measures); or any re-occurrence of non-DLT G3 non-hematologic 
event. Additional protocol specific DLTs were: G4 fistula; G3 cardiac disorder; hemorrhage or 
hypertension if uncontrolled with medication; G2 thromboembolic event or pulmonary 
hemorrhage; or any grade intracranial hemorrhage, gastrointestinal perforation, trachea-
esophageal fistula, or reversible posterior leukoencephalopathy. The MTD was defined as the 
dose level below any dose level with more than one DLT. 
Pharmacokinetic assessments 
For the dose-escalation part of the study, PK blood samples were collected before and after each 
infusion with additional samples obtained on Days 8 and 22 (7 days after the first two infusions). 
For the expansion cohort, blood was collected before and after the infusions on Days -14 and 1 
(bevacizumab only), Day -2 (RO5323441 only), and at all other dosing occasions (combination 
treatment). Additional samples were obtained on Days 8 and 22. Except for Day -14, pre-
infusion samples were taken <3 hours prior to the dynamic contrast-enhanced (DCE)-MRI scan. 
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Serum free bevacizumab concentrations were determined by ELISA using recombinant human 
VEGF for capture and goat anti-human IgG conjugated to horseradish peroxidase for detection 
as described previously.21 RO5323441 quantification was performed using a sandwich ELISA 
with immobilized biotinylated recombinant human PlGF as capture reagent and digoxigenylated 
(F(ab’)2-specific) sheep polyclonal anti-RO5323441 antibody with horseradish peroxidase-
conjugated anti-digoxigenin Fab fragments as detection reagents. Only RO5323441 with free and 
active binding sites were detected with the analytical method. 
Pharmacodynamic assessments 
For the expansion cohort only, the pharmacological effect of RO5323441 on vascular parameters 
was investigated by DCE-MRI and diffusion-weighted (DW)-MRI conducted twice at baseline 
and on Days -2, 1, 15, and 53–55 (Figure 1A). Image acquisition was performed before, during 
and after the IV administration of a gadolinium contrast agent, while patients were on a stable 
dose of steroids for at least five days. DCE-MRI was conducted before any study drug treatment 
scheduled for the same day. Image acquisition was performed locally and analysis of the scans 
conducted centrally. 
Plasma PlGF, VEGFA and fms-related tyrosine kinase-4 (FLT4) levels were quantified using 
immunological multi-parametric chip technique (IMPACT) analysis as part of a Roche solid 
phase antibody sandwich ELISA. Blood was collected on Days 1, 8, 15, 29, 53–55, 85, and every 
3 months thereafter, with additional samples on Days -14 and -2 in the expansion cohort only. 
For VEGFA, this assay detects both free VEGFA and part of the bound VEGFA. 
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Efficacy assessments 
Tumor response was evaluated every 8 weeks using Revised Assessment in Neuro-Oncology 
(RANO) criteria,22 which combine radiological tumor assessment with neurological assessment 
whilst taking into account corticosteroid use. Disease imaging was performed locally and scans 
were interpreted by a single radiologist at each site, wherever possible. ORR, best overall 
response, disease control rate (DCR), median progression-free survival (PFS), 6-month PFS rate 
(PFS-6), and median overall survival (OS) were calculated. DCR was defined as the rate of 
combined complete responses, partial responses, and stable disease as assessed by RANO 
criteria. 
Statistical considerations 
All patients who received at least one dose of study medication were included in the safety and 
efficacy populations. DCE-/DW-MRI parameters were evaluated using a within-patient change 
from baseline. Median time-to-event for PFS and OS was analyzed using Kaplan-Meier 
estimates.  
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RESULTS 
Patient characteristics and treatment 
Twenty-two patients were enrolled into three dose groups (Table 1). All patients had received 
previous TMZ treatment with radiotherapy, after surgery. All patients received 10 mg/kg 
bevacizumab. Cumulative RO5323441 doses ranged from 2.5 g to 60 g. Patients received a 
median of eight doses (range: 1–27) of both RO5323441 and bevacizumab. Sixteen patients 
discontinued the study due to progressive disease, one withdrew consent, and two patients 
discontinued the study due to DLTs. Three other patients were withdrawn by the investigator 
after complete metabolic responses on 18F-FDG PET scans after they had experienced objective 
anatomic responses (2 CR, 1 PR) for up to 18 months while on study treatment. These patients 
were censored in PFS and OS analyses. 
Safety 
Two DLTs were reported in two patients. One patient experienced G3 meningitis associated with 
cerebrospinal fluid (CSF) leak 12 days after the second dose of RO5323441 (1250 mg) and 
bevacizumab. This patient had received surgery to resect the right uncus 1 month prior to first 
dose of study drug. The epidural/subgaleal CSF leakage observed at the time of meningitis was 
first noted 6 weeks previously, and it was believed that bevacizumab might have caused or 
compromised regression of pre-existing CSF leakage which enhanced the risk of infection. The 
second DLT (G3 cerebral infarction) occurred 5 days after the first dose of combination therapy 
(2500 mg RO5323441). No MTD was reached and the highest dose of RO5323441 tested was 
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2500 mg. Sixteen (73%) patients died due to disease progression following study 
discontinuation, whereas the remaining patients were alive. 
146 AEs were reported in 21 patients (Table 2) including 31 G3/4 AEs (in 17 patients). Fifty-five 
study drug-related AEs occurred in 20 patients, including hypertension (13 patients/59%), 
dysphonia (11/50%), epistaxis (4/18%) and fatigue (3/14%). The incidence and severity of AEs 
and drug-related AEs were similar across dosing groups. Of the 21serious AEs (SAEs) reported 
in 13 patients, only hypertension, pulmonary embolism, confusion, and pneumonia occurred in 
more than one patient. All SAEs of hypertension and pulmonary embolism, meningitis 
associated with spinal fluid leak, upper abdominal pain, and cerebral infarction were considered 
to be study drug-related. Four other SAEs were deemed possibly related but unexpected. 
There were no apparent dose-related changes in vital signs, physical examinations, performance 
status, ECGs, or laboratory parameters. All final visit lower extremity ultrasounds were normal. 
Pharmacokinetics 
Linear dose-dependent increases in peak and trough concentrations of RO5323441 were 
observed (Supplementary Table S1). The PK parameters of RO5323441 were estimated using a 
two-compartment population PK model. The average effective half-life was 18.5±8.0 days and 
the mean apparent clearance was 0.19±0.05 L/day. The mean estimated volume of distribution 
was 2.9±0.6 L for the central compartment and 2.1±1.5 L for the peripheral compartment. The 
mean area under the concentration-time curve over the dosing interval (AUCtau) at steady state 
was 4884±1142, 6075±1019, and 12762±3183 µg*day/mL for the 625, 1250, and 2500 mg dose 
levels, respectively (the linear dose-exposure relationship is shown in Supplementary Figure S1). 
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Bevacizumab serum exposures were similar across cohorts, and were unaffected by the 
concomitant administration of RO5323441 (Supplementary Table S2). 
Pharmacodynamics 
Following initial treatment with single-agent bevacizumab (on Day-14), DCE-MRI analysis 
revealed a large relative decrease from baseline (~60% by Day-2) in initial area under the 
gadolinium concentration curve normalized with plasma input function (AUCBN). AUCBN is a 
composite parameter that reflects flow, permeability and vascular volume.23 This effect 
(observed in all evaluated lesions in all patients) was maintained for the duration of combination 
therapy (Figure 1B and 1C). A further decrease (Day -2 to Day 1) occurred for two patients after 
RO5323441 dosing. All patients also showed a marked decrease (~70% overall) in DCE-MRI-
derived fractional extracellular extravascular volume (e; Figure 1D). DW-MRI revealed an 
overall smaller decrease (~20%) in the water diffusion coefficient (ADC) and a reduction in 
ADC was observed in 4/6 patients (5/7 tumor lesions; Figure 1E). 
Baseline median plasma PlGF level (available for 21 patients) was 24.4 pg/mL (range: 14.1–
31.3 pg/mL). In the expansion cohort, the median baseline PlGF level was 25.5 pg/mL (range: 
20–31.3 pg/mL) which increased by approximately 40% after a single dose of bevacizumab. In 
all cohorts, there was no apparent association between baseline PlGF levels and clinical 
response. The combined effect of bevacizumab plus RO5323441 on PlGF levels could not be 
evaluated due to assay interference caused by RO5323441. 
Increases in VEGFA were observed following the administration of both combination therapy 
(cohorts 1–3) and bevacizumab monotherapy (cohort 4; Figure 2A). Following prolonged 
combination treatment, the levels of VEGFA appeared to increase to a greater extent with the 
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highest tested dose of RO5323441 (cohorts 3 and 4). Although results were variable, decreased 
levels of FLT4 occurred following the administration of both treatments (Figure 2B). 
Efficacy 
Of the 22 treated patients, one (4.5%) patient had a complete response, four (18.2%) had a partial 
response, 11 (50%) had stable disease, and six (27.2%) had progressive disease (Supplementary 
Table S3 and Figure 3A). Two patients experienced prolonged durable responses of 16 and 17 
months after treatment with 1250 mg and 625 mg RO5323441, respectively. One patient had no 
on-treatment response assessments and was therefore considered to have progressive disease. 
These findings translate into an ORR of 22.7% and a DCR of 72.7%. No dose-dependent effect 
was observed. 
Median PFS was 3.5 months (95% CI, 2.6–4.3 months; Figure 3B) and median OS was 
8.5 months (95% CI, 7.3–9.9 months; Figure 3C). PFS-6 was 22.7% and the Kaplan-Meier 
estimate for 6-month OS was 81.8%. 
Corticosteroid use decreased in six (38%) of 16 patients who received corticosteroids at baseline 
(median dose reduction -50%, range -20% to -80%). 
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DISCUSSION 
RO5323441 in combination with bevacizumab had acceptable tolerability in patients with 
recurrent glioblastoma. Two DLTs occurred, which led to patient withdrawal; however, the 
MTD for the combination was not reached. The highest RO5323441 dose tested was 2500 mg. 
The safety profile of RO5323441 was similar across dose groups and no patient died while on 
the study. Hypertension was also the most frequent treatment-related AE (64% of patients) but 
was well managed with medication and did not lead to study discontinuations. The reason for the 
higher frequency of hypertension compared with previous studies with single-agent 
RO532344119 (5%) or single-agent bevacizumab24 (30–40%; 4–11% G3/4) remains unclear. This 
may reflect the 30–50% higher RO5323441 exposure seen in this study compared with that seen 
in patients with hepatocellular, ovarian and colorectal cancer treated with equivalent RO5323441 
doses as monotherapy/combination therapy (Roche, unpublished data). Conversely, bevacizumab 
exposure was not affected by co-administration with RO5323441. Dysphonia, which is 
uncommon with single-agent bevacizumab24 and single-agent RO5323441,18,19 occurred 
frequently with combination therapy and may indicate a synergistic toxicity; however, all events 
were grade I/II. 
Consistent with the known anti-angiogenic effects of bevacizumab,25 VEGF inhibition was 
associated with a large decrease in DCE-MRI AUCBN. Further reductions in AUCBN occurred in 
two patients following subsequent administration of RO5323441, which may indicate an additive 
anti-angiogenic effect. The reductions in DW-MRI ADC and DCE-MRI e reported here are 
comparable to previous results with other anti-angiogenic treatments.15 This suggests that the 
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two agents may be capable of reducing vasogenic edema, a finding that has been previously 
reported with bevacizumab.11,26 Bevacizumab therapy can also decrease (peri-)tumoral edema in 
patients with recurrent glioblastoma, thereby reducing the demand for corticosteroids.27 This is 
consistent with the reduction in dexamethasone dose seen in 38% of patients who were receiving 
steroids at baseline in the current study. 
Increases in plasma PlGF levels occur in patients with glioblastoma treated with anti-VEGF 
therapies15,28 and may represent an escape mechanism to anti-angiogenic therapy.29 In this study, 
baseline plasma PlGF levels were comparable with previous results15 and increased moderately 
following bevacizumab administration. The influence of RO5323441 on PlGF levels could not 
be assessed due to interference of RO5323441with the assay. Across all cohorts, there was no 
apparent association between baseline PlGF levels and clinical response.  
Bevacizumab therapy can increase levels of VEGF and decrease levels of VEGFRs.30,31 PlGF 
has been proposed to stimulate angiogenesis by displacing VEGF from the ‘VEGFR-1 sink’, 
thereby increasing the fraction of VEGFA available to activate VEGFR-2.32 Hence, neutralizing 
of PlGF by escalating doses of RO5523441 should decrease VEGFA levels by allowing 
increased binding of VEGF to VEGFR-1. However, apparently greater increase in VEGFA 
levels were seen in patients treated at the highest dose of RO5323441 (Figure 2A), suggesting a 
(over-) compensatory feedback mechanism of VEGFA expressing tumor cells. Moreover, 
increasing doses of RO5523441 may also reduce the formation of PlGF/VEGF heterodimers33 
which consequently increases VEGFA levels. 
The ORR was 22.7% with no apparent differences between RO5323441 dose groups (no formal 
comparison of RO5323441 dose level and efficacy was conducted due to the low number of 
patients treated with the lower doses). Six month PFS was 22.7% and median OS was 8.5 
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months. These results are similar to previous findings with single-agent bevacizumab in 
recurrent glioblastoma,10,11 including the recent BELOB34 and CABARET35 studies (16–24% 
PFS-6). While dual inhibition of VEGF and PlGF did not increase the ORR compared with 
previous studies of single-agent bevacizumab, two patients did experience durable responses of 
16 and 17 months, respectively. The value of PlGF as a therapeutic target in cancer remains 
undetermined.36,37 Results with aflibercept, which binds both VEGFR and PlGF, have also been 
disappointing in patients with glioblastoma (PFS-6 was 7.7%), despite the encouraging activity 
of this agent in other cancers.38 
In summary, the safety and tolerability of multiple-dose RO5323441 and bevacizumab was 
acceptable and manageable and the MTD for the combination therapy was not determined. While 
our study was not designed to test the efficacy of RO5323441, the data suggests that dual anti-
VEGF and anti-PlGF inhibition with bevacizumab and RO5323441 in recurrent glioblastoma 
offers no therapeutic advantage over that which can be achieved with bevacizumab alone. The 
clinical development of RO5323441 has been terminated by the sponsor following an overall 
portfolio review. 
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CAPTIONS FOR ILLUSTRATIONS 
Figure 1. Effect of anti-angiogenic treatment on DCE-MRI and DW-MRI parameters for the six 
patients (seven tumors) in the expansion cohort. DCE-MRI/DW-MRI was performed twice at 
baseline and prior to any scheduled study drug on Day -2 (2 weeks after the first dose of single-
agent bevacizumab), Day 1, Day 15, and on Day 53–55 (A). Overall relative change from 
baseline in median AUCBN (B) and individual profiles for the relative change from baseline in 
median AUCBN (C), median e (D) and median ADC (E) are indicated. ADC, water diffusion 
coefficient; AUCBN, area under the gadolinium concentration curve normalized with plasma 
input function; BL, baseline; DCE-MRI, dynamic contrast-enhanced magnetic resonance 
imaging; DW-MRI, diffusion-weighted magnetic resonance imaging; PD, progressive disease; 
q2w, once every 2 weeks; e, fractional extracellular extravascular volume 
Figure 2. Effect of anti-angiogenic treatment on plasma levels of VEGFA (A) and FLT4 (B). All 
patients received bevacizumab 10 mg/kg combined with 625 mg (Cohort 1), 1250 mg (Cohort 2) 
or 2500 mg (Cohorts 3 and 4) RO5323441 q2w. Combination dosing began on Day 1 in cohorts 
1–3. In cohort 4 (expansion cohort) patients received single-agent bevacizumab on Day -14 and 
Day 1, single-agent RO5323441 on Day -2, with combination dosing beginning on Day 15. 
Means of the relative change from baseline over time for each cohort are displayed. FLT4, fms-
related tyrosine kinase-4; VEGFA, vascular endothelial growth factor A 
Figure 3. Anti-tumor activity of RO5323441 and bevacizumab in glioblastoma patients. 
Waterfall plot showing maximum change in SLDs compared with baseline (A) and Kaplan-
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Meier curves of progression-free survival (B) and overall survival (C) for all patients. Figure 3A 
shows the data for 19 patients as two patients had no target lesions and one patient had no post-
treatment tumor assessments. Tick marks on Kaplan-Meier curves indicate censored data. BOR, 
best overall response; CR, complete response; PD, progressive disease; PR, partial response; 
RANO, Revised Assessment in Neuro-Oncology; SD, stable disease; SLD, summed longest 
tumor diameter 
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Table 1. Patient characteristics (N=22) 
 RO5323441 dose 
Parameter 
625 mg 
N=4 
1250 mg 
N=6 
2500 mg 
N=12a 
All 
N=22 
Gender, n (%)     
Male 2 (50) 5 (83) 9 (75) 16 (73) 
Female 2 (50) 1 (17) 3 (25) 6 (27) 
Age,  
median (range)  
60.0 
(50–66) 
58.0 
(41–69) 
57.0 
(37–72) 
58.0 
(37–72) 
Weight in kg,  
median (range) 
73.0 
(48.6–92.8) 
83.5 
(69.4–95.0) 
75.0 
(62.0–98.0) 
79.5 
(48.6–98.0) 
BMI in kg/m2,  
median (range) 
24.4 
(18.8–26.3) 
26.4 
(22.7–31.3) 
25.6 
(20.0–31.4) 
25.7 
(18.8–31.4) 
Corticosteroid use 
n (%)  
2 (50) 3 (50) 11 (92) 16 (73) 
aIncludes patients from both the dose-escalation (n=6) and expansion cohort parts (n=6) of the 
study. 
BMI, body mass index 
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Table 2. Adverse events of any grade reported by >10% of the study population and 
all G 3/4 events 
Event Patients by treatment group and AE grade 
(n [%]) 
625 mg 
N=4 
1250 mg 
N=6 
2500 mg 
N=12 
All 
N=22 
AE leading to discontinuation − 1 (17) 1 (8) 2 (9) 
SAE 1 (25) 5 (83) 7 (58) 13 (59) 
Any grade AE in >10% patients     
Hypertension 3 (75) 3 (50) 8 (67) 14 (64) 
Headache 3 (75) 4 (67) 5 (42) 12 (55) 
Dysphonia 1 (25) 2 (33) 8 (67) 11 (50) 
Fatigue 2 (50) 1 (17) 3 (25) 6 (27) 
Nasopharyngitis - 1 (17) 4 (33) 5 (23) 
Arthralgia - 2 (33) 2 (17) 4 (18) 
Constipation 1 (25) 1 (17) 2 (17) 4 (18) 
Epistaxis 1 (25) 1 (17) 2 (17) 4 (18) 
Nausea - 1 (17) 2 (17) 3 (14) 
All G 3/4 events     
Hypertension 3 (75) 2 (33) 6 (50) 11 (56) 
Headache 1 (25) - 1 (8) 2 (9) 
Pneumonia - 1 (17) 1 (8) 2 (9) 
Confusion 1 (25) 1 (17) - 2 (9) 
Pulmonary embolism - 1 (17) 1 (8) 2 (9) 
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Fatigue - 1 (17) - 1 (5) 
Deep vein thrombosis 1 (25) - - 1 (5) 
Device-related infection - - 1 (8) 1 (5) 
Meningitis associated with spinal fluid 
leak 
- 1 (17)a - 1 (5) 
Sepsis - - 1 (8) 1 (5) 
Tooth abscess - - 1 (8) 1 (5) 
Urinary tract infection - - 1 (8) 1 (5) 
Brain edema - - 1 (8) 1 (5) 
Cerebral infarction - - 1 (8)a 1 (5) 
Asthenia - - 1 (8) 1 (5) 
Mucosal inflammation - - 1 (8) 1 (5) 
Abdominal pain upper - - 1 (8) 1 (5) 
a  Indicates the two dose-limiting toxicities. AE, adverse event; G, grade; SAE, serious adverse 
event 
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Supplementary Figure S1. Exposure of RO5323441 according to the dose of RO5323441 
administered. Approximately linear dose-dependent increases in serum exposure of RO5323441 
were observed. The figure shows the relationship between the mean area under the 
concentration-time curve over the dosing interval (AUCtau) and dose. 
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Supplementary Table S1. Summary of RO5323441 peak and trough serum concentrations 
  Infusion 1 Infusion 2 Infusion 3 Infusion 4 
Dose Measurement Peak Trough Peak Trough Peak Trough Peak 
625 mga N 4 4 4 4 4 4 4 
 Mean concentration (μg/mL) 208 89 330 143 358 162 415 
 CV% 25 25 18 27 27 33 33 
1250 mga N 6 6 6 5 5 5 5 
 Mean concentration (μg/mL) 382 126 527 180 620 227 641 
 CV% 28 27 24 35 23 32 25 
2500 mga N 5 5 5 5 5 5 5 
 Mean concentration (μg/mL) 895 255 1228 402 1310 499 1450 
 CV% 16 27 17 34 13 24 15 
2500 mgb N 6 6 6 6 6 6 6 
 Mean concentration (μg/mL) 916  258 1182 411 1337 508 1417 
 CV% 28 21 16 20 16 33 17 
aDose-escalation part of the study. Patients received intravenous infusions of RO5323441 on Day 
1 and every 2 weeks thereafter. 
bExpansion cohort part of the study. Patients received intravenous infusions of RO5323441 on 
Day -2, Day 15 and every 2 weeks thereafter. CV, coefficient of variation 
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Supplementary Table S2. Summary of bevacizumab peak and trough serum concentrations 
  Infusion 1 Infusion 2 Infusion 3 Infusion 4 
RO5323441 
dose Measurement Peak Trough Peak Trough Peak Trough Peak 
625 mga N 3b 4 4 4 4 4 4 
 Mean concentration (μg/mL) 243 88 309 151 394 183 447 
 CV% 31 6 25 11 18 13 19 
1250 mga N 6 6 6 5 5 5 5 
 Mean concentration (μg/mL) 259 89 309 134 412 194 471 
 CV% 18 15 14 27 15 14 12 
2500 mga N 6 5 5 5 5 5 5 
 Mean concentration (μg/mL) 275 82 342 136 426 176 470 
 CV% 21 29 31 24 21 37 17 
  Infusion 1 Infusion 2 Infusion 3 Infusion 4 Infusion 5 
RO5323441 
dose Measurement Peak 
Troug
h Peak 
Troug
h Peak 
Troug
h Peak 
Troug
h Peak 
2500 mgc N 6 6 6 6 6 6 6 6 6 
 Mean concentration (μg/mL) 239 75 293 119 319 137 347 162 394 
 CV% 17 30 22 28 22 28 22 23 17 
aDose-escalation part of the study. Patients received intravenous infusions of bevacizumab on 
Day 1 and every 2 weeks thereafter. 
bOne value was identified as a pharmacokinetic outlier and excluded (2005 μg/mL). cExpansion 
cohort part of the study. Patients received intravenous infusions of bevacizumab on Day -14, Day 
1 and every 2 weeks thereafter. CV, coefficient of variation 
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Supplementary Table S3. Response to treatment (RANO) 
 RO5323441 
625 mg 
N=4 
RO5323441 
1250 mg 
N=6 
RO5323441 
2500 mg 
N=12a 
 
Total 
N=22 
Objective response 1 (25.0%) 1 (16.7%) 3 (25.0%) 5 (22.7%) 
Complete response 0 1 (16.7%) 0 1 (4.5%) 
Partial response 1 (25.0%) 0 3 (25.0%) 4 (18.2%) 
Stable disease 3 (75.0%) 4 (66.7%) 4 (33.3%) 11 (50.0%) 
Progressive disease 0 1 (16.7%) 4 (33.3%)a 6 (27.2%) 
aOne patient treated with 2500 mg RO5323441 had no on-treatment tumor assessment and was 
therefore considered to have progressive disease. 
RANO, Revised Assessment in Neuro-Oncology 
 
